STAT

Opinion: The economic rationale for strong action now against Covid-19

Although the economic costs of combating #Covid19 epidemic are already large and mounting, now is the time to use the U.S.'s immense resources to contain the disease and mitigate its…
Traders work during the opening bell at the New York Stock Exchange Monday. Trading on Wall Street was halted immediately after the opening bell Monday, as stocks posted steep losses following emergency moves by the Federal Reserve to try to avert a recession due to the coronavirus pandemic.

As governments and communities struggle to figure out the best way to deal with the novel coronavirus, a major concern is how to balance the risk to lives versus the risk to livelihoods. In short, how do we balance the public health versus economic consequences of this pandemic?

The answer comes from a widely used economic tool, and it is telling us that extreme measures are warranted.

It is difficult to (VSL) to think about the trade-off between the risk of dying and money. For example, how much more are you willing to pay for upgraded safety features on a car?

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks